Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Dec;18(6):419-421.
doi: 10.1159/000534589. Epub 2023 Oct 16.

Breast Cancer Outcome: What Have We Achieved

Volker Möbus  1 , Marcus Schmidt  2
Affiliations
Editorial

Breast Cancer Outcome: What Have We Achieved

Volker Möbus et al. Breast Care (Basel). 2023 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Volker Möbus declares no conflict of interest. Marcus Schmidt reports personal fees from AstraZeneca, BioNTech, Daiichi Sankyo, Eisai, Lilly, MSD, Novartis, Pantarhei Bioscience, Pfizer, Pierre Fabre, Roche, and Seagen. His institution has received research funding from AstraZeneca, BioNTech, Eisai, Genentech, German Breast Group, Novartis, Palleos, Pantarhei Bioscience, Pierre Fabre, and Seagen. In addition, he has a patent for EP 2390370 B1 and a patent for EP 2951317 B1 issued.

References

    1. Nitz UA, Gluz O, Kümmel S, Christgen M, Braun M, Aktas B, et al. . Endocrine therapy response and 21-gene expression assay for therapy guidance in HR+/HER2- early breast cancer. J Clin Oncol. 2022;40(23):2557–67. - PubMed
    1. Tolaney SM, Tarantino P, Graham N, Tayob N, Parè L, Villacampa G, et al. . Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 2023;24(3):273–85. - PubMed
    1. Cortes J, Pérez-García JM, Ruiz-Borrego M, Stradella A, Bermejo B, Escrivá-de-Romaní S, et al. . 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC). J Clin Orthod. 2023;41(17_Suppl l):LBA506.
    1. van der Voort A, van Ramshorst MS, van Werkhoven ED, Mandjes IA, Kemper I, Vulink AJ, et al. . Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial. JAMA Oncol. 2021;7:978–84. - PMC - PubMed
    1. Banys-Paluchowski M, Rubio IT, Ditsch N, Krug D, Gentilini OD, Kühn T. Real de-escalation or escalation in disguise? Breast. 2023;69:249–57. - PMC - PubMed

Publication types

LinkOut - more resources